ERBB2 and endometrial cancer: IMPLICATIONS FOR PATIENT CARE: HER2- and CD24-targeted immuno-PET could prove valuable in the clinic as a theranostic tool to identify patients with endometrial cancer who are likely to respond to HER2- and CD24-targeted therapeutics.